DCT

1:26-cv-00184

PH Health Ltd v. ARS Pharma Operations Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00184, D. Del., 02/19/2026
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendant is a Delaware corporation and is subject to personal jurisdiction in the district.
  • Core Dispute: Plaintiffs allege that Defendant’s submission of a New Drug Application for its Neffy® epinephrine nasal spray constitutes an act of infringement of four patents related to stable epinephrine formulations.
  • Technical Context: The technology concerns pharmaceutical formulations of epinephrine, a critical drug for treating severe allergic reactions, with improved stability and reduced formation of degradants to extend shelf life.
  • Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendant's submission of New Drug Application (NDA) No. 214697 for its Neffy® product. On January 7, 2026, Defendant provided Plaintiffs with a notice letter containing a Paragraph IV Certification for U.S. Patent Nos. 9,119,876, 9,295,657, and 12,280,024, alleging non-infringement, invalidity, and/or unenforceability. The complaint states it was filed within the 45-day statutory window following receipt of this notice. The patents-in-suit are listed in the FDA’s Orange Book in connection with NDA No. 204200 for Adrenalin® (epinephrine injection). Plaintiffs also assert U.S. Patent No. 10,130,592, for which Defendant did not submit a Paragraph IV Certification.

Case Timeline

Date Event
2015-03-13 Earliest Priority Date for ’876, ’657, ’592, and ’024 Patents
2015-09-01 U.S. Patent No. 9,119,876 Issues
2016-01-14 ’876 Patent Listed in FDA Orange Book
2016-03-29 U.S. Patent No. 9,295,657 Issues
2016-04-12 ’657 Patent Listed in FDA Orange Book
2018-11-20 U.S. Patent No. 10,130,592 Issues
2025-04-22 U.S. Patent No. 12,280,024 Issues
2025-04-25 ’024 Patent Listed in FDA Orange Book
2026-01-07 Defendant's Notice Letter Date
2026-02-19 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,119,876 - "Epinephrine formulations," Issued September 1, 2015

The Invention Explained

  • Problem Addressed: The patent describes that existing pharmaceutical epinephrine formulations, such as Adrenalin®, have a limited shelf life due to chemical degradation (Compl. ¶21; ’876 Patent, col. 1:57-60). This degradation leads to the formation of impurities, including epinephrine sulfonic acid (ESA) and D-epinephrine (an enantiomer with insignificant therapeutic activity), which can compromise the product's efficacy and safety over time (’876 Patent, col. 1:60 - col. 2:6).
  • The Patented Solution: The invention proposes an improved epinephrine-containing pharmaceutical composition designed to be more stable and resist degradation (’876 Patent, col. 2:7-10). The solution involves a specific formulation that includes not only epinephrine but also a combination of excipients: a tonicity regulating agent, a pH raising agent (as part of a buffer system), an antioxidant, a pH lowering agent, and a transition metal complexing agent, all within specified concentration ranges (’876 Patent, abstract; ’876 Patent, col. 2:31-43).
  • Technical Importance: Developing more stable epinephrine formulations is significant for ensuring the reliability and extending the shelf life of a critical emergency medical product used to treat life-threatening conditions like anaphylaxis (’876 Patent, col. 1:25-30).

Key Claims at a Glance

The complaint does not identify specific claims but alleges infringement of "one or more claims" of the ’876 Patent (Compl. ¶36). Independent claim 1 is representative:

  • A composition comprising:
    • in the range of about 0.5 to 1.5 mg/mL of epinephrine and/or salts thereof;
    • in the range of about 6 to 8 mg/mL of a tonicity regulating agent;
    • in the range of about 2.8 to 3.8 mg/mL of a pH raising agent;
    • in the range of about 0.1 to 1.1 mg/mL of an antioxidant;
    • in the range of about 0.001 to 0.010 mL/mL of a pH lowering agent; and
    • in the range of about 0.01 to 0.4 mg/mL of a transition metal complexing agent;
    • wherein the antioxidant comprises sodium bisulfite and/or sodium metabisulfite.

U.S. Patent No. 9,295,657 - "Epinephrine formulations," Issued March 29, 2016

The Invention Explained

  • Problem Addressed: Like the related ’876 Patent, the ’657 Patent addresses the problem of limited shelf life and degradation of existing epinephrine formulations, which results in the formation of impurities (’657 Patent, col. 1:58 - col. 2:6).
  • The Patented Solution: The patent claims a method of treating various medical conditions by administering a specific, stabilized epinephrine composition (’657 Patent, col. 2:50-54). The composition itself is similar to that described in the ’876 Patent, containing epinephrine along with a system of excipients including a tonicity regulating agent, a pH raising agent, an antioxidant, a pH lowering agent, and a transition metal complexing agent to enhance stability (’657 Patent, abstract).
  • Technical Importance: By claiming a method of use for a more stable formulation, the patent seeks to protect the application of this improved technology in treating critical conditions such as anaphylaxis and cardiac arrhythmias (’657 Patent, col. 1:25-33).

Key Claims at a Glance

The complaint alleges infringement of "one or more claims" of the ’657 Patent (Compl. ¶47). Independent claim 1 is a representative method claim:

  • A method of treating a condition comprising administering to a patient in need thereof a composition comprising:
    • in the range of about 0.5 to 1.5 mg/mL of epinephrine and/or salts thereof;
    • in the range of about 6 to 8 mg/mL of a tonicity regulating agent;
    • in the range of about 2.8 to 3.8 mg/mL of a pH raising agent;
    • in the range of about 0.1 to 1.1 mg/mL of an antioxidant;
    • in the range of about 0.001 to 0.010 mL/mL of a pH lowering agent; and
    • in the range of about 0.01 to 0.4 mg/mL of a transition metal complexing agent;
    • wherein the antioxidant comprises sodium bisulfite and/or sodium metabisulfite, and wherein the condition is selected from a specified group including anaphylaxis.

U.S. Patent No. 12,280,024 - "Epinephrine formulations," Issued April 22, 2025

  • Technology Synopsis: This patent, from the same family as the ’876 and ’657 patents, is also directed to improved epinephrine-containing pharmaceutical compositions that address the stability and shelf-life limitations of prior art formulations (’024 Patent, col. 2:7-13). The invention focuses on a specific formulation of components intended to reduce the formation of degradants such as ESA and D-epinephrine (’024 Patent, col. 2:10-13).
  • Asserted Claims: The complaint does not specify which claims are asserted (Compl. ¶58). The patent contains one independent claim (Claim 1).
  • Accused Features: The complaint alleges that the epinephrine composition within Defendant's Proposed NDA Product infringes the ’024 Patent (Compl. ¶58).

U.S. Patent No. 10,130,592 - "Epinephrine formulations," Issued November 20, 2018

  • Technology Synopsis: Also part of the same patent family, the ’592 Patent discloses pharmaceutical compositions comprising epinephrine that are designed to have improved stability and lower levels of impurities compared to existing products (’592 Patent, col. 2:7-10). The claimed composition includes epinephrine, an antioxidant, a buffer system with tartaric acid, a tonicity regulating agent, a preservative, and a transition metal complexing agent (’592 Patent, claim 1).
  • Asserted Claims: The complaint does not specify which claims are asserted (Compl. ¶69). The patent contains one independent claim (Claim 1).
  • Accused Features: The complaint alleges that the epinephrine composition within Defendant's Proposed NDA Product infringes the ’592 Patent (Compl. ¶69).

III. The Accused Instrumentality

  • Product Identification: The accused instrumentality is Defendant ARS Pharmaceuticals Operations, Inc.'s "Neffy® (epinephrine nasal spray) drug product," referred to as the "Proposed NDA Product" (Compl. ¶1).
  • Functionality and Market Context: The complaint describes the Proposed NDA Product as an epinephrine nasal spray for which Defendant is seeking FDA approval via NDA No. 214697 (Compl. ¶1). The complaint alleges, on information and belief, that the Defendant's NDA refers to and relies upon the data for Plaintiffs' Adrenalin® (epinephrine) product and contains data to demonstrate bioequivalence (Compl. ¶27). The Defendant is seeking approval to commercially manufacture and sell the product in the United States prior to the expiration of the patents-in-suit (Compl. ¶6). No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide specific, element-by-element infringement allegations or a claim chart. Instead, Plaintiffs plead infringement on "information and belief," stating that they lack the information related to Defendant's NDA necessary to meaningfully evaluate the basis for infringement and must resort to the judicial process and discovery to obtain such information (Compl. ¶¶35, 46, 57, 67). This pleading style is asserted in reliance on the Federal Circuit's holding in Hoffman-La Roche Inc. v. Invamed Inc. (Compl. ¶35). The core of the infringement allegation is the conclusory statement that the Proposed NDA Product uses an "epinephrine composition as covered by one or more of the claims" of each patent-in-suit (Compl. ¶¶36, 47, 58, 69).

  • Identified Points of Contention:
    • Factual Questions: A central factual dispute, pending discovery of the NDA, will be whether the specific chemical formulation of Neffy®—including the identity and concentration of its active ingredient and all excipients—falls within the ranges recited in the asserted claims of the patents-in-suit.
    • Scope Questions: The patents-in-suit repeatedly describe the invention in the context of an "epinephrine injection" suitable for subcutaneous, intracameral, or intramuscular administration (’876 Patent, col. 1:41-43). The accused product is a "nasal spray" (Compl. ¶1). This raises the question of whether the claimed "composition" is limited to injectable formulations or can be construed broadly enough to cover a formulation designed for nasal administration.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for a definitive analysis of claim construction disputes. However, based on the technology and the nature of the accused product, certain terms may become central to the case.

  • The Term: "composition" (e.g., ’876 Patent, claim 1)

    • Context and Importance: The definition of this term is critical because the accused product is a nasal spray, while the patents’ specifications heavily emphasize injectable solutions. Practitioners may focus on this term because Defendant may argue that the specification limits the scope of "composition" to formulations suitable for injection, thereby designing around the claims.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The term "composition" itself is general and is not explicitly limited to a particular delivery form in the language of the claim.
      • Evidence for a Narrower Interpretation: The specification repeatedly refers to "Adrenalin®, a sympathomimetic agent" as an exemplary prior art product, which is an "epinephrine injection" (’876 Patent, col. 1:40-42). The detailed description also discusses administration via "subcutaneous, intracameral, intravenous, and intramuscular injection" (’876 Patent, col. 3:13-15). This repeated focus on injectables could be used to argue for a narrower construction.

  • The Term: "pH raising agent" (e.g., ’876 Patent, claim 1)

    • Context and Importance: This term is a required functional element of the claimed composition. The dispute will likely center on whether an excipient in the Neffy® formulation performs this specific function within the context of the patent's disclosure, or if it has a different primary purpose.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The patent describes the "pH raising agent" as part of a "buffer system" that "may provide a resistance to significant change in pH" (’876 Patent, col. 3:58-61). This functional language could support a broader definition covering any substance that contributes to this buffering effect.
      • Evidence for a Narrower Interpretation: The patent provides specific examples of pH raising agents, such as "tartaric acid and sodium hydroxide" (’876 Patent, col. 5:23-25). A defendant might argue that the term should be construed in light of these examples and that its chosen excipient does not function in the same way or is chemically distinct.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon FDA approval, Defendant will actively induce infringement by instructing healthcare providers and others to use the Proposed NDA Product in accordance with its proposed labeling (Compl. ¶¶38-39; Compl. ¶¶49-50; Compl. ¶¶60-61; Compl. ¶¶71-72). The complaint also alleges that Defendant knew of the patents-in-suit when it submitted its NDA (Compl. ¶¶40, 51, 62, 73).
  • Willful Infringement: The complaint does not contain an explicit allegation of willful infringement. It alleges that Defendant had knowledge of the patents-in-suit when it submitted its NDA (Compl. ¶¶40, 51, 62, 73). The prayer for relief requests a declaration that the case is "exceptional" for the purpose of awarding attorneys' fees under 35 U.S.C. § 285, but does not explicitly request enhanced damages for willfulness (Compl. Prayer for Relief ¶e).

VII. Analyst’s Conclusion: Key Questions for the Case

  • A core issue will be one of definitional scope: can the term "composition," as disclosed in patents heavily focused on injectable solutions, be construed to cover the formulation of the accused Neffy® nasal spray, or did the patentees implicitly limit their invention to injectable forms?
  • A key evidentiary question, which can only be resolved after discovery of the Defendant's confidential NDA, will be one of factual correspondence: does the specific chemical formulation of the Neffy® product, including the identity and concentration of all excipients, meet every limitation of at least one asserted patent claim?
Loading Complaint